MKI67 and cancer: We examined several of these cancer cell hallmarks following treatment of VCaP cells with single SSO doses and observed a significant reduction in VCaP cell proliferation in SSO-treated cells 48–96 h following dosing as assessed by Ki67 staining (Fig. 3a, b).